The event, hosted at the Lotte New York Palace Hotel in New York, runs from September 14 through September 16, 2026. Intensity’s president and chief executive officer, Lewis H. Bender, will attend the conference to conduct one-on-one meetings with investors. The company’s presentation will be available for on-demand viewing starting at 7:00 am ET on September 11 via the firm’s investor relations portal, with archived replays accessible for 90 days.

At the center of the company’s current pipeline is INT230-6, an investigational candidate designed to saturate tumors with cytotoxic agents while triggering a localized immune response. Unlike traditional systemic chemotherapy, this approach aims to turn malignant cells into a source of neoantigens without causing widespread immunosuppression. Intensity is currently advancing several clinical programs, including the INVINCIBLE-3 Phase 3 trial for soft tissue sarcoma and the INVINCIBLE-4 Phase 2 study targeting triple-negative breast cancer in collaboration with the Swiss Cancer Institute.